GSK

GSK, the UK's second-largest pharmaceutical company, is currently in the news due to several key developments. Most notably, GSK is acquiring RAPT, a Californian biotech company, for $2.2 billion. This acquisition gives GSK access to RAPT's drug aimed at preventing severe food allergies. This marks the first major deal under GSK's new CEO, Luke Miels. Furthermore, researchers are hailing new antibiotic treatments developed by GSK as a potential "turning point" in combating drug-resistant strains of gonorrhea, a globally rising infection. These advancements highlight GSK's ongoing efforts in developing innovative treatments and addressing critical public health concerns. The company's activities demonstrate its continued relevance in the pharmaceutical industry and its commitment to tackling global health challenges.